Objective
Pertussis vaccines have been very successful in reducing the global burden of pertussis-related disease. However, in the last decade there has been a rise in pertussis incidence, particularly in vaccinated adolescents and adults in industrialized countries. The increased circulation of B. pertussis (Bp) constitutes a risk for transmission to vulnerable infants and older adults. Additionally, immunity in humans has been shown to wane rapidly after immunization with pertussis vaccines, especially with acellular pertussis (aP) vaccines, suggesting that the improved reactogenicity profile of aP compared to whole cell pertussis vaccines, may be accompanied by differences in duration of immunity. The key objectives of PERISCOPE are to 1. identify biomarkers of protection against Bp colonization and disease; 2. foster scientific innovation and rebuild the ecosystem and technical infrastructure needed in Europe to allow the future evaluation of novel pertussis vaccine candidates and 3. improve understanding of the pathogenesis of Bp infection and its potential impact on the recently observed changes in pertussis epidemiology. To reach these objectives, PERISCOPE brings together a selected group of internationally recognized public and EFPIA partners with strong expertise in clinical trials, immunology, molecular microbiology, human and animal challenge models and bioinformatics. We will initiate a series of (pre)clinical studies and develop harmonized human and animal challenge models, standardized assays and cutting-edge techniques to unravel the innate and adaptive responses to Bp. This will allow us to identify biomarkers of protection and durable immunity. PERISCOPE will thus facilitate the accelerated development and registration of novel pertussis vaccines and/or guide optimal use of vaccination strategies. The introduction of improved pertussis vaccines will help to reduce the global burden of pertussis.
Fields of science
Not validated
Not validated
- medical and health scienceshealth sciencesinfectious diseasesRNA viruses
- medical and health sciencesbasic medicineimmunologyimmunisation
- medical and health scienceshealth sciencespublic healthepidemiology
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
- medical and health sciencesclinical medicineobstetrics
Keywords
Programme(s)
Funding Scheme
RIA - Research and Innovation actionCoordinator
6525 GA Nijmegen
Netherlands
See on map
Participants (25)
OX1 2JD Oxford
See on map
LS2 7UE Leeds
See on map
59019 Lille
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
75654 Paris
See on map
D02 CX56 Dublin
See on map
20014 Turku
See on map
75015 PARIS 15
See on map
Participation ended
SW7 2AZ LONDON
See on map
3721 MA Bilthoven
See on map
142 00 Praha 4
See on map
4051 Basel
See on map
Legal entity other than a subcontractor which is affiliated or legally linked to a participant. The entity carries out work under the conditions laid down in the Grant Agreement, supplies goods or provides services for the action, but did not sign the Grant Agreement. A third party abides by the rules applicable to its related participant under the Grant Agreement with regard to eligibility of costs and control of expenditure.
4056 Basel
See on map
BA2 7AY Bath
See on map
2333 ZA Leiden
See on map
37008 Salamanca
See on map
1050 Bruxelles / Brussel
See on map
1011 Lausanne
See on map
SO17 1BJ Southampton
See on map
9052 Gent
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
Participation ended
SN2 1FL Swindon
See on map
66386 St Ingbert
See on map
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
69007 Lyon
See on map
1330 Rixensart
See on map
WC1E 7HT London
See on map
Participation ended
6525 XZ Nijmegen
See on map